Skip to main content
. 2021 Apr 15;7(5):792–802. doi: 10.1021/acscentsci.0c01186

Figure 1.

Figure 1

Repurposing FDA-approved drugs for SARS-CoV-2 through cellular screening. (A) Summary of methodology used in this paper. (B) Screening for FDA-approved small molecule therapeutics for activities in suppressing SARS-CoV-2 replication in Vero E6 cells. Dose–response curves in the suppression of SARS-CoV-2 replication in Vero E6 cells and cytotoxicity for simeprevir (C) and remdesivir (D) are shown. Data points in all plots represent mean ± S.E.M. For all data points, n = 3 replicates.